Einstein-Montefiore Clinical and Translational Science Award Hub

阿尔伯特·爱因斯坦的哈罗德和穆里尔布洛克临床和翻译研究所(卢旺达问题国际法庭) 医学院和蒙特菲奥里医学中心是我们CTSA项目的所在地。世界银行的愿景 卢旺达问题国际法庭将改善布朗克斯和其他遭受不成比例和不公正痛苦的社区的健康状况。 通过加速将生物医学发现转化为有效和 可持续的疾病防治战略。卢旺达问题国际法庭成立于2007年，已经改变了临床和 通过创建强大的研究环境，在爱因斯坦和蒙特菲奥雷范围内进行翻译研究(CTR)； 设计CTR流程；整合研究和医疗保健；发展强大的社区 两性关系。卢旺达问题国际法庭“在布朗克斯区及以外建造桥梁”的主题强调了#年的重要性。 弥合我们的研究人员、卫生系统领导者、临床医生、患者、社区和CTSA之间的差距 促进翻译科学和卫生公平的合作伙伴。卢旺达问题国际法庭的具体目标是：(1)催化 将提高翻译研究的效率和效果的创新。我们将提供支持和资金 具有克服主要CTR障碍和卫生不平等的高潜力研究；创建方法学和 信息学翻译科学创新；改进CTR操作，加强传播和 实施战略。(2)及早并在整个过程中与社区、患者和其他合作伙伴接触 翻译过程。我们新的社区和利益相关者参与度研究模块将改变我们的 把学习型卫生系统打造成“学习型卫生研究共同体”，促进双向互动 与社区、患者和其他合作伙伴沟通；促进研究，以确定和缓解社会 健康的决定因素，并加强目标人群对循证方案的接受。(3)发展和发展 实施最先进的临床研究和信息学资源和服务，以提高严密性、安全性、 CTR的效率、有效性和普适性。(4)培养、发展和保持一支熟练的、多学科的、 和多样化的翻译员工队伍，通过新的培训和途径支持和领导高质量的研究 确保历史上被排斥群体的成员参与CTR并成为研究领导者的计划。(5) 与其他CTSA枢纽和CTSA联盟合作，加快CTR并快速响应紧急公众 健康需求。我们的目标与新的CTSA方案目标保持一致，并将使卢旺达问题国际法庭能够最大限度地 为国家协作CTSA联盟的集体努力做出贡献，以向 更多的病人更快地在布朗克斯和更远的地方。

The Harold and Muriel Block Institute for Clinical and Translational Research (ICTR) at the Albert Einstein College of Medicine and Montefiore Medical Center serves as the home of our CTSA program. The vision of the ICTR is to improve the health of the Bronx, and other communities that disproportionately and unjustly suffer from poor heath and premature death, by accelerating the translation of biomedical discoveries into effective and sustainable disease prevention and treatment strategies. Created in 2007, the ICTR has transformed clinical and translational research (CTR) throughout Einstein and Montefiore by creating a robust research environment; re- engineering CTR processes; integrating research and healthcare; and developing strong community relationships. The ICTR theme of “Building Bridges in the Bronx and Beyond” underscores the importance of bridging gaps between our researchers, health system leaders, clinicians, patients, communities, and CTSA partners to advance translational science and health equity. The specific aims of the ICTR are to: (1) Catalyze innovations that will enhance the efficiency and effectiveness of translational research. We will support and fund studies with high potential to overcome major CTR roadblocks and health inequities; create methodological and informatics translational science innovations; improve CTR operations, and enhance dissemination and implementation strategies. (2) Engage communities, patients, and other partners early and throughout the translational process. Our new Community and Stakeholder Engagement Research module will transform our learning health system into a “learning health research community”; promote active and continuous bidirectional communication with communities, patients and other partners; facilitate research to identify and mitigate social determinants of health, and enhance uptake of evidence-based programs by target populations. (3) Develop and implement state-of-the-art clinical research and informatics resources and services to improve the rigor, safety, efficiency, effectiveness, and generalizability of CTR. (4) Train, develop, and maintain a skilled, multidisciplinary, and diverse translational workforce to support and lead high quality research with new training and pathway programs to ensure members of historically excluded groups engage in CTR and become research leaders. (5) Partner with other CTSA hubs and the CTSA consortium to accelerate CTR and rapidly respond to urgent public health needs. Our aims are aligned with the new CTSA program goals and will enable the ICTR to maximally contribute to the collective efforts of the national collaborative CTSA consortium to deliver more treatments to more patients more quickly in the Bronx and beyond.